Lifecore Biomedical, Inc.
LFCR
$7.24
-$0.52-6.70%
NASDAQ
| 05/25/2025 | 02/23/2025 | 11/24/2024 | 08/25/2024 | 05/26/2024 | |
|---|---|---|---|---|---|
| Revenue | 0.47% | 7.23% | 16.47% | 23.42% | 24.20% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 0.47% | 7.23% | 16.47% | 23.42% | 24.20% |
| Cost of Revenue | 2.50% | -2.74% | 2.26% | 5.80% | 14.78% |
| Gross Profit | -3.71% | 34.71% | 57.30% | 79.95% | 49.55% |
| SG&A Expenses | 7.18% | 15.25% | 13.38% | 12.05% | 0.74% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.47% | 2.44% | 5.35% | 7.27% | 9.15% |
| Operating Income | -67.80% | 35.16% | 59.26% | 66.45% | 69.68% |
| Income Before Tax | -506.50% | -122.28% | 67.82% | 108.29% | 114.88% |
| Income Tax Expenses | -76.50% | -110.00% | -44.89% | -82.14% | -40.58% |
| Earnings from Continuing Operations | -514.93% | -116.98% | 67.66% | 108.14% | 114.53% |
| Earnings from Discontinued Operations | -- | -99.24% | 103.32% | 102.83% | 107.59% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -422.29% | -121.19% | 80.30% | 106.58% | 112.07% |
| EBIT | -67.80% | 35.16% | 59.26% | 66.45% | 69.68% |
| EBITDA | -201.57% | 74.00% | 101.79% | 101.06% | 128.05% |
| EPS Basic | -431.05% | -118.57% | 79.18% | 106.73% | 111.90% |
| Normalized Basic EPS | -330.91% | -670.23% | 48.94% | 124.05% | 131.90% |
| EPS Diluted | -676.98% | -75.87% | 76.05% | 101.53% | 106.85% |
| Normalized Diluted EPS | -486.53% | -5,114.50% | 42.18% | 112.23% | 119.06% |
| Average Basic Shares Outstanding | 14.23% | 9.46% | 4.23% | 1.70% | 2.03% |
| Average Diluted Shares Outstanding | 3.93% | -0.45% | 4.16% | 11.75% | 12.14% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |